43 completed, 4 terminated, 3 recruiting, 1 not yet recruiting. 24 Phase 3, 12 Phase 4, 7 Not applicable, 6 Phase 2, 4 Phase 1.
Follow Lubiprostone: new trials by email Literature Review of Lubiprostone trials Research Report on Lubiprostone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lubiprostone Combined With Maintenance Therapy for Prevention of Postoperative Recurrence in Peritoneal Metastatic Colorectal Cancer maintenance therapy plus lubiprostone, maintenance therapy - Colorectal Cancer Metastatic, Peritoneal (Metastatic) Cancer | Phase 2 | Not yet recruiting | Sun Yat-sen University | 124 | 2026-02-24 | 2026-02-12 |
| Efficacy and Safety of Lubiprostone in the Treatment of Slow Transit Constipation Lubiprostone, Polyethylene glycol (PEG ) - Slow Transit Constipation, Pharmacotherapy | Phase 3 | Recruiting | Third Military Medical University | 346 | 2025-11-13 | 2026-08-05 |
| Anorectal Manometery in Pediatric Chronic Refractory Constipation lubiprostone , single arm, biofeed back sessions, botox injection - Chronic Constipation | Phase 1 / Phase 2 | Recruiting | Ain Shams University | 60 | 2024-09-07 | 2024-10-09 |
| Lubiprostone for Functional Constipation in the Under 18 Years Patients Lubiprostone Pill, Lactulose Oral Liquid Product, Bisacodyl 5 MG - Clinical Efficacy, Treatment Efficacy | Phase 3 | Completed | Alexandria University | 274 | 2022-01-01 | 2022-11-15 |
| Efficacy and Tolerability of Lubiprostone in Patients With Nonalcoholic Fatty Liver Disease Lubiprostone 24Mcg Oral twice daily - NAFLD | Phase 3 | Completed | Helwan University | 116 | 2020-11-01 | 2023-12-13 |
| Colon Preparation With 2L PEG in Combination With Lubiprostone vs 4L PEG polyethylene glycol in combination with lubiprostone, polyethylene glycol alone - Indication for Modification of Patient Status (Diagnosis) | Phase 4 | Completed | Department of Medical Services Ministry of Public Health of Thailand | 140 | 2019-12-01 | 2021-08-11 |
| Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation Naldemedine, Lubiprostone, Naloxegol - Opioid-induced Constipation | Recruiting | BioDelivery Sciences International | 34532 | 2019-01-04 | 2026-09-30 | |
| Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo Lubiprostone, Placebo - Chronic Idiopathic Constipation | Phase 3 | Completed | Sucampo Pharma Americas, LLC | 552 | 2017-03-13 | 2020-01-14 |
| Comparative Pharmacokinetics and Food-Effect Bioavailability of Lubiprostone Sprinkle in Healthy Volunteers Cohort 1: Lubiprostone Capsule, Fasted, Cohort 1: Lubiprostone Sprinkle Formulation, Fasted, Cohort 2: Lubiprostone Sprinkle Formulation, Fed - Healthy Volunteers | Phase 3 | Completed | Sucampo Pharma Americas, LLC | 49 | 2016-11-16 | 2020-03-09 |
| Lubiprostone for Chronic Idiopathic Constipation Treatment Lubiprostone, Placebo - Constipation | Phase 3 | Completed | Takeda | 211 | 2016-05-11 | 2019-04-01 |
| Lubiprostone for Treatment of Chronic Idiopathic Constipation Placebo, Lubiprostone - Chronic Idiopathic Constipation | Phase 3 | Completed | Takeda | 156 | 2016-04-14 | 2018-12-31 |
| Evaluation of the Safety of Lubiprostone in Pediatric Participants Aged ≥ 6 Years to < 18 Years With Functional Constipation Lubiprostone - Constipation - Functional | Phase 3 | Completed | Sucampo Pharma Americas, LLC | 87 | 2016-04-12 | 2020-05-15 |
| Lubiprostone for the Treatment of Chronic Idiopathic Constipation Lubiprostone, Placebo - Constipation | Phase 3 | Completed | Takeda | 204 | 2016-03-02 | 2018-08-13 |
| A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adults BLI400 Laxative, Lubiprostone - Chronic Idiopathic Constipation | Phase 3 | Completed | Braintree Laboratories | 459 | 2015-05-01 | 2020-07-27 |
| Evaluation of the Efficacy and Safety of Lubiprostone in Adults With Mixed or Unsubtyped Irritable Bowel Syndrome Lubiprostone, Placebo - Irritable Bowel Syndrome | Phase 2 | Terminated | Sucampo Pharma Americas, LLC | 71 | 2015-02-01 | 2019-12-27 |
| Lubiprostone for Children With Constipation Lubiprostone - Constipation - Functional | Phase 3 | Completed | Sucampo Pharma Americas, LLC | 419 | 2014-02-26 | 2020-01-21 |
| Lubiprostone in Children With Functional Constipation Lubiprostone, Placebo - Constipation - Functional | Phase 3 | Completed | Sucampo Pharma Americas, LLC | 606 | 2013-12-13 | 2020-07-21 |
| Pharmacodynamic, Pharmacokinetic, and Tolerability Study of a Liquid Form of Lubiprostone in Adult Subjects With Chronic Idiopathic Constipation Lubiprostone, Placebo - Chronic Idiopathic Constipation | Phase 3 | Completed | Mallinckrodt | 164 | 2013-10-01 | 2019-12-13 |
| Lubiprostone as a Modulator of Gut Microbial Translocation in HIV With Incomplete CD4 Recovery on Antiretroviral Therapy Lubiprostone - HIV | Phase 2 | Completed | Ruth M. Rothstein CORE Center | 20 | 2013-06-01 | 2023-08-30 |
| Evaluation of Clinical Equivalence Between Two Lubiprostone Products in the Treatment of Chronic Idiopathic Constipation Lubiprostone, Placebo - Chronic Idiopathic Constipation | Phase 3 | Completed | Dr. Reddy's Laboratories Limited | 909 | 2012-10-01 | 2014-04-03 |
Showing 20 of 51. Sign in to see all of them.
Constipation (17) · Irritable Bowel Syndrome (5) · Opioid-Induced Constipation (5) · Colorectal Neoplasms (2) · Parkinson Disease (2) · Cystic Fibrosis (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 1 (1) · Diabetes Mellitus, Type 2 (1) · Disease (1) · Drug-Related Side Effects and Adverse Reactions (1) · Inflammatory Bowel Diseases (1) · Multiple Sclerosis (1) · Neoplasm Metastasis (1) · Neoplasms (1)
Sucampo Pharma Americas, LLC (13) · Takeda (3) · Augusta University (2) · Brooke Army Medical Center (2) · Mayo Clinic (2) · Texas Tech University Health Sciences Center, El Paso (2) · University of Arkansas (2) · University of South Alabama (2) · Ain Shams University (1) · Alexandria University (1) · Anchen Pharmaceuticals, Inc (1) · Asian Institute of Gastroenterology, India (1) · Baylor College of Medicine (1) · BioDelivery Sciences International (1) · Braintree Laboratories (1)
United States (39) · Canada (5) · Belgium (3) · Egypt (3) · Poland (3) · United Kingdom (3) · France (2) · Netherlands (2) · China (1) · Czechia (1) · Germany (1) · Mexico (1) · Russia (1) · South Korea (1) · Sweden (1)
Andrew D Goodman, MD (1) · Ann L Silverman, MD (1) · Apichet Sirinawasatien, MD (1) · Ashis Patnaik, M.D (1) · Catherine E. O'Brien, Pharm.D. (1) · Christina M Marciniak, MD (1) · Edy E Soffer, MD (1) · Egilius L.H. Spierings, M.D., Ph.D. (1) · Gregory Huhn, MD, MPHTM (1) · Irene Sarosiek, MD (1)
PMID 21160617, PMID 24716835, PMID 33834354, PMID 33838349, PMID 12135020, PMID 12838225, PMID 15139050, PMID 15758907, PMID 16630226, PMID 17413599, PMID 17916109, PMID 18541153, PMID 18684185, PMID 18686757, PMID 19006537, PMID 19033530, PMID 19136102, PMID 19137119, PMID 19404263, PMID 19537839, PMID 19577749, PMID 20614462, PMID 20647400, PMID 20883845, PMID 20957375, PMID 21115134, PMID 21162694, PMID 22251419, PMID 22573627, PMID 23261065, PMID 23480216, PMID 23898382, PMID 25158925, PMID 25473191, PMID 25617726, PMID 25916220, PMID 27033126, PMID 27046523, PMID 27127190, PMID 27650225, PMID 27737636, PMID 27922028, PMID 31945360, PMID 37211380, PMID 38256369, PMID 39744921, PMID 7380204
K24DK002638 (1), R01DK054681 (1), UL1RR024150 (1)